PMID: 9187447Jan 1, 1997Paper

Radioimmunotherapy strategies for non-Hodgkin's lymphomas

Annals of Oncology : Official Journal of the European Society for Medical Oncology
M C CorcoranO W Press

Abstract

Radioimmunotherapy offers an exciting new therapeutic modality for patients with relapsed non-Hodgkin's lymphoma; however, considerable debate exists regarding the optimal dose and administration schedule for radioimmunoconjugates. Myelosuppression has been the dose-limiting toxicity of most clinical trials employing radiolabeled antibodies, and this complication has generated both high-dose and low-dose treatment strategies. 'Low-dose' strategies are nonmyeloablative and rely upon repetitive infusions to effectively eradicate tumor masses. Trials incorporating low-dose radioimmunotherapy have documented high response rates, though the durability of these responses remains unclear. The most encouraging nonmyeloablative studies have documented objective responses in 70%-80% of patients, complete responses in 30%-50% of patients, minimal toxicity, and a median response duration of 12 months. In contrast, high-dose trials performed in conjunction with autologous hematopoietic stem cell transplantation have demonstrated objective responses in 95% of patients, complete responses in 85% of patients, with a progression-free survival of 62% and an overall survival of 93% with a median follow-up of two years. Toxicities are considerably...Continue Reading

Citations

Nov 30, 2000·Current Treatment Options in Cardiovascular Medicine·F M RosenbergB M McManus
Aug 1, 2000·Clinical Privilege White Paper
Sep 24, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C BuskeW Hiddemann
Mar 9, 2000·Pharmaceutical Science & Technology Today·S V GovindanG L Griffiths

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

Baillière's Clinical Haematology
J Brissinck, S J Russell
Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie
H A Moritz, S S Azad
Der Internist
F WeissingerM Wilhelm
© 2021 Meta ULC. All rights reserved